Parkman Healthcare Partners’s UroGen Pharma URGN Stock Holding History

Parkman Healthcare Partners’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.41M	Sell	174,064 -100,936	-37%	-$2.74M	0.66%	51
2026 Q1	$4.94M	Buy	275,000 +106,232	+63%	+$2.13M	0.51%	55
2025 Q4	$3.95M	Sell	168,768 -233,827	-58%	-$5.07M	0.38%	70
2025 Q3	$8.03M	Buy	402,595 +225,893	+128%	+$4.06M	0.84%	43
2025 Q2	$2.42M	Sell	176,702 -216,451	-55%	-$2.08M	0.28%	78
2025 Q1	$4.35M	Buy	393,153 +23,292	+6%	+$248K	0.52%	56
2024 Q4	$3.94M	Buy	369,861 +22,320	+6%	+$267K	0.52%	52
2024 Q3	$4.41M	Buy	347,541 +73,076	+27%	+$1.08M	0.56%	57
2024 Q2	$4.61M	Buy	274,465 +90,281	+49%	+$1.28M	0.62%	57
2024 Q1	$2.76M	Buy	184,184 +8,684	+5%	+$142K	0.34%	74
2023 Q4	$2.63M	Buy	175,500 +30,189	+21%	+$392K	0.37%	68
2023 Q3	$2.04M	Buy	+145,311	New	+$2.33M	0.37%	73

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Parkman Healthcare Partners's URGN Position: Q2 2026 in Review

Parkman Healthcare Partners reduced its UroGen Pharma (URGN) stake by 37% in Q2 2026, selling an estimated $2.74M and leaving 174,064 shares worth $6.41M. The position accounts for 0.66% of the portfolio, ranked #51.

Parkman Healthcare Partners first reported a position in URGN in Q3 2023 and has held it in 12 quarters since. The position peaked at $8.03M in Q3 2025. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Parkman Healthcare Partners held 174,064 shares of UroGen Pharma worth $6.41M as of Q2 2026.
Parkman Healthcare Partners sold 100,936 UroGen Pharma shares in Q2 2026, an estimated $2.74M.
UroGen Pharma made up 0.66% of Parkman Healthcare Partners's portfolio in Q2 2026, its #51 holding.
Parkman Healthcare Partners first reported a position in UroGen Pharma in Q3 2023 and has held it in 12 quarters since.
Parkman Healthcare Partners's UroGen Pharma position peaked at $8.03M in Q3 2025.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.